Improving Patient Safety Through Access to Sugammadex in the PACU Setting

Authors

Dominique Donatelli, Corewell Health Resident
Roy Soto, Corewell Health

Document Type

Conference Proceeding

Publication Date

10-20-2024

Abstract

Prior to development of Sugammadex the frequency of residual neuromuscular paralysis in PACU has been documented to range from 4-50%. Residual paralysis is associated with many postoperative complications including hypoxia and respiratory failure. Following an incidence of inadequate muscular paralysis reversal leading to respiratory decompensation in PACU, we instituted a change in the way providers have access to Sugammadex within this setting. Sugammadex vials are now stocked within PACU Omnicell for urgent access and within the crash cart for emergent need. Providers have given positive feedback regarding this institutional change

Comments

American Society of Anesthesiologists Annual Meeting, October 18-22, 2024, Philadelphia, PA

Recommended Citation

Donatelli D, Soto R. Improving patient safety through access to sugammadex in the PACU setting. Presented at: American Society of Anesthesiologists Annual Meeting; 2024 Oct 20; Philadelphia, PA. Available from:https://www.abstractsonline.com/pp8/#!/20183/presentation/8399